NCT01592383 · OUTCOME

OS

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma · Source last updated 2018-10-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: 1 year

What was measured

Overall survival measured as the time from study enrollment until death.

Analysis population: The study was terminated early after the enrollment of two participants and the data were not collected.

Groups in this outcome

Treatment (Enzyme Inhibitor Therapy)

Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. erlotinib hydrochloride: Given PO laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Enzyme Inhibitor Therapy)	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
units
Participants

description

Overall survival measured as the time from study enrollment until death.

groups

description
Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. erlotinib hydrochloride: Given PO laboratory biomarker analysis: Correlative studies
id
OG000
title
Treatment (Enzyme Inhibitor Therapy)

population Description

The study was terminated early after the enrollment of two participants and the data were not collected.

reporting Status

POSTED

time Frame

1 year

title

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice